KHK 4083

Drug Profile

KHK 4083

Alternative Names: KHK4083

Latest Information Update: 31 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Atopic dermatitis

Most Recent Events

  • 15 May 2018 Kyowa Hakko Kirin plans a phase II trial for Atopic dermatitis in USA, Europe and Japan in 2019
  • 07 Feb 2018 Kyowa Hakko Kirin Pharma completes a phase-I clinical trials in Atopic dermatitis in Japan (IV) (NCT03096223)
  • 26 Dec 2017 Kyowa Hakko Kirin Pharma completes a phase I trial for Ulcerative colitis in Japan (IV and SC) (NCT02985593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top